Literature DB >> 11127651

Erythrocyte transfusion causes immunosuppression after total hip replacement.

S J Kendall1, J Weir, R Aspinall, D Henderson, J Rosson.   

Abstract

A prospective study of 34 patients undergoing total hip replacement was done to determine whether homologous erythrocyte transfusion causes postoperative immunosuppression. In the transfused patient group (14 patients), there was a reduction in CD3+ and CD3+4+ cell numbers at Day 2, returning to preoperative levels by Day 7. In contrast, in the untransfused patient group (20 patients), there was no significant depression in these lymphocyte subgroups at Day 2 and an increase in total lymphocyte, CD3+, CD3+4+, and CD3+4-8- cell numbers at Day 7. In both patient groups there was postoperative leukocytosis, granulocytosis, and monocytosis at Days 2 and 7, with no significant change in postoperative B (CD19+) cell numbers, natural killer cells, or the minor T cell populations of CD3+4+8+ and CD3+25+. The lymphocyte functional test of Candida recall was significantly impaired at Day 7 in the transfused patient group, where Candida recall is a memory T cell response to an antigen extracted from the yeast Candida Albicans. These findings suggest that homologous erythrocyte transfusion after hip replacement surgery causes cell mediated immune suppression. The main clinical implication of the current study is that perioperative homologous erythrocyte transfusion may place patients at greater risk of infectious complications, including infection of the prosthesis.

Entities:  

Mesh:

Year:  2000        PMID: 11127651     DOI: 10.1097/00003086-200012000-00018

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  8 in total

1.  Attitudes to blood transfusion post arthroplasty surgery in the United Kingdom: a national survey.

Authors:  Simon W Young; Daniel J Marsh; Mohammed A Akhavani; Cameron G Walker; John A Skinner
Journal:  Int Orthop       Date:  2007-03-30       Impact factor: 3.075

2.  2010 Mid-America Orthopaedic Association Physician in Training Award: predictors of early adverse outcomes after knee and hip arthroplasty in geriatric patients.

Authors:  Carlos A Higuera; Karim Elsharkawy; Alison K Klika; Matthew Brocone; Wael K Barsoum
Journal:  Clin Orthop Relat Res       Date:  2011-02-23       Impact factor: 4.176

3.  Identification and treatment of anaemia in patients awaiting hip replacement.

Authors:  B A Rogers; A Cowie; C Alcock; J W Rosson
Journal:  Ann R Coll Surg Engl       Date:  2008-09       Impact factor: 1.891

4.  Postoperative use of non-steroidal anti-inflammatory drugs in patients with anastomotic leakage requiring reoperation after colorectal resection: cohort study based on prospective data.

Authors:  Mads Klein; Ismail Gögenur; Jacob Rosenberg
Journal:  BMJ       Date:  2012-09-26

5.  Despite Inflammation, Supplemented Essential Amino Acids May Improve Circulating Levels of Albumin and Haemoglobin in Patients after Hip Fractures.

Authors:  Roberto Aquilani; Ginetto Carlo Zuccarelli; Anna Maria Condino; Michele Catani; Carla Rutili; Consiglia Del Vecchio; Pietro Pisano; Manuela Verri; Paolo Iadarola; Simona Viglio; Federica Boschi
Journal:  Nutrients       Date:  2017-06-21       Impact factor: 5.717

6.  Outcomes, Microbiology and Antimicrobial Usage in Pressure Ulcer-Related Pelvic Osteomyelitis: Messages for Clinical Practice.

Authors:  Clark D Russell; Shao-Ting Jerry Tsang; Alasdair Hamish R W Simpson; Rebecca K Sutherland
Journal:  J Bone Jt Infect       Date:  2020-03-26

7.  Reducing surgical site infection in arthroplasty of the lower limb: A multi-disciplinary approach.

Authors:  R Johnson; S S Jameson; R D Sanders; N J Sargant; S D Muller; R M D Meek; M R Reed
Journal:  Bone Joint Res       Date:  2013-03-01       Impact factor: 5.853

8.  Innate immunity recovers earlier than acquired immunity during severe postoperative immunosuppression.

Authors:  Gunnar Lachmann; Clarissa von Haefen; Johannes Kurth; Fatima Yuerek; Claudia Spies
Journal:  Int J Med Sci       Date:  2018-01-01       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.